Kilitch Drugs India Ltd vs Mercury Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Kilitch Drugs (India) Ltd is ₹ 154.85 as of 06 May 15:30 . The P/E Ratio of Kilitch Drugs (India) Ltd changed from 34.2 on March 2021 to 21.8 on March 2025 . This represents a CAGR of -8.61% over 5 yearsThe P/E Ratio of Mercury Laboratories Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Kilitch Drugs (India) Ltd changed from ₹ 125.58 crore on March 2021 to ₹ 581.3 crore on March 2025 . This represents a CAGR of 35.86% over 5 yearsThe Market Cap of Mercury Laboratories Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Kilitch Drugs (India) Ltd for the Dec '25 is ₹ 55.34 crore as compare to the Sep '25 revenue of ₹ 55.58 crore. This represent the decline of -0.43% The revenue of Mercury Laboratories Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Kilitch Drugs (India) Ltd for the Dec '25 is ₹ 7.68 crore as compare to the Sep '25 ebitda of ₹ 11.7 crore. This represent the decline of -34.36% The ebitda of Mercury Laboratories Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Kilitch Drugs (India) Ltd changed from ₹ 0.11 crore to ₹ 4.32 crore over 7 quarters. This represents a CAGR of 714.53% The net profit of Mercury Laboratories Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Kilitch Drugs (India) Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Mercury Laboratories Ltd changed from 7.87 % on March 2021 to 13.38 % on March 2025 . This represents a CAGR of 11.20% over 5 years .

About Kilitch Drugs (India) Ltd

Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe.
Their extensive research efforts have led to development of comprehensive, diverse and highly complementary portfolio of medicines targeting a wide spectrum of chronic and acute treatments which includes Sterile dosages namely Injectables & Ophthalmic, Effervescent tablets & Granules, Tablets & Capsules, OTC range covering varied Nutraceuticals & Cosmetics and Medical devices. The Company is engaged in development, manufacturing and marketing of quality finished dosages.
The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia.

About Mercury Laboratories Ltd

Mercury Laboratories Limited, the registered partnership firm started its business activity in year 1962.
Subsequently, it converted into Private Limited Company & incorporated in February, 1982.
Later, it converted into Limited Company in 1992 in Maharashtra.
The Company has obtained ISO 9001:2008 registrations.
It is engaged into the manufacturing and export of wide range of Pharmaceutical items.

FAQs for the comparison of Kilitch Drugs (India) Ltd and Mercury Laboratories Ltd

Which company has a larger market capitalization, Kilitch Drugs (India) Ltd or Mercury Laboratories Ltd?

Market cap of Kilitch Drugs (India) Ltd is 541 Cr while Market cap of Mercury Laboratories Ltd is 93 Cr

What are the key factors driving the stock performance of Kilitch Drugs (India) Ltd and Mercury Laboratories Ltd?

The stock performance of Kilitch Drugs (India) Ltd and Mercury Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Kilitch Drugs (India) Ltd and Mercury Laboratories Ltd?

As of May 6, 2026, the Kilitch Drugs (India) Ltd stock price is INR ₹154.85. On the other hand, Mercury Laboratories Ltd stock price is INR ₹775.0.

How do dividend payouts of Kilitch Drugs (India) Ltd and Mercury Laboratories Ltd compare?

To compare the dividend payouts of Kilitch Drugs (India) Ltd and Mercury Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.